The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis
Open accessAbstract
Background Amyloid-related imaging abnormalities (ARIA) have been reported in patients with Alzheimer's disease treated with bapineuzumab, a humanised monoclonal antibody against amyloid β. ARIA include MRI signal abnormalities suggestive of vasogenic oedema and sulcal effusions (ARIA-E) and microhaemorrhages and haemosiderin deposits (ARIA-H). Our aim was to investigate the incidence of ARIA during treatment with bapineuzumab, and evaluate associated risk factors.Methods Two neuroradiologists independently reviewed 2572 fluid-attenuated inversion recovery (FLAIR) MRI scans from 262 participants in two phase 2 studies of bapineuzumab and an open-label extension study. Readers were masked to the patient's treatment, APOE ɛ4 genotype, medical history, and demographics. Patients were included in risk analyses if they had no evidence of ARIA-E in their pre-treatment MRI, had received bapineuzumab, and had at least one MRI scan after treatment. We used Kaplan-Meier survival analysis to examine the distribution of incident ARIA-E from the start of bapineuzumab treatment and proportional hazards regression models to assess risk factors associated with ARIA.Findings 210 patients were included in the risk analyses. 36 patients (17%) developed ARIA-E during treatment with bapineuzumab; 15 of these ARIA-E cases (42%) had not been detected previously. 28 of these patients (78%) did not report associated symptoms. Adverse events, reported in eight symptomatic patients, included headache, confusion, and neuropsychiatric and gastrointestinal symptoms. Incident ARIA-H occurred in 17 of the patients with ARIA-E (47%), compared with seven of 177 (4%) patients without ARIA-E. 13 of the 15 patients in whom ARIA were detected in our study received additional treatment infusions while ARIA-E were present, without any associated symptoms. Occurrence of ARIA-E increased with bapineuzumab dose (hazard ratio [HR] 2·24 per 1 mg/kg increase in dose, 95% CI 1·40-3·62; p=0·0008) and presence of APOE ɛ4 alleles (HR 2·55 per allele, 95% CI 1·57-4·12; p=0·0001).Interpretation ARIA consist of a spectrum of imaging findings with variable clinical correlates, and some patients with ARIA-E remain asymptomatic even if treatment is continued. The increased risk of ARIA among APOE ɛ4 carriers, its association with high bapineuzumab dose, and its timecourse in relation to dosing suggest an association between ARIA and alterations in vascular amyloid burden.Funding Elan Corporation, Janssen Alzheimer Immunotherapy, Wyeth Pharmaceuticals, and Pfizer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The main adverse effects associated with administration of certain anti-Aβ mAbs during clinical trials were amyloid related imaging abnormalities (ARIA) identified on magnetic resonance imaging (MRI) scans.”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However one needs to be mindful that escalation of anti-Aβ mAbs dose in APOE ε4 allele carriers may trigger increased rate of vasculotropic adverse events associated with immunization [5, 8, 14].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, ApoE genotyping is now increasingly considered an important component of the pre-treatment work-up for anti-amyloid therapies [5, 8, 11, 12].”
From Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era (2026) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The greater incidence of these abnormalities with increasing bapineuzumab dose and number of APOEε4 alleles is consistent with phase 2 findings.11,13”
From Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease (2014) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Some amyloid β antibodies triggered amyloid-related imaging abnormalities (ARIAs) in clinical trials and ARIAs tend to be more frequent in APOE4 carriers [28].”
From Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease (2017) · cites this paper as [28]
The cited source says what the claim attributes to it.
In the citing paper
“These included vasogenic edema (ARIA-E) and cerebral microhemorrhages (ARIA-H) that in about 20% of cases are associated with clinical symptoms and signs [13, 14].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“These included vasogenic edema (ARIA-E) and cerebral microhemorrhages (ARIA-H) that in about 20% of cases are associated with clinical symptoms and signs [13, 14].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Frequency of ARIA events and in particular ARIA-E was significantly higher among APOE ε4 allele carriers compared to non-carriers, making the APOE ε4 allele a risk factor for vascular complications of anti-Aβ immunotherapy [5, 8, 14, 15].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Frequency of ARIA events and in particular ARIA-E was significantly higher among APOE ε4 allele carriers compared to non-carriers, making the APOE ε4 allele a risk factor for vascular complications of anti-Aβ immunotherapy [5, 8, 14, 15].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, ApoE ε4 status has gained direct clinical relevance in the anti-amyloid era”
From Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“ε4 carriers, particularly ε4 homozygotes, exhibit a substantially increased risk of amyloid-related imaging abnormalities (ARIA) during treatment with anti-amyloid monoclonal antibodies [2, 5, 8].”
From Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era (2026) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT
Wahlund, L., Barkhof, F., Fazekas, F., Bronge, L., Augustin, M., Sjögren, M., Wallin, A., Adèr, H., Leys, D., Pantoni, L., et al. (2001) · Stroke · doi:10.1161/01.str.32.6.1318 · Cited by 1,838
Pathologic correlates of incidental MRI white matter signal hyperintensities
Fazekas, F., Kleinert, R., Offenbacher, H., Schmidt, R., Kleinert, G., Payer, F., Radner, H., & Lechner, H. (1993) · Neurology · doi:10.1212/wnl.43.9.1683 · Cited by 1,619
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857
Self-citationPrevalence and risk factors of cerebral microbleeds: The Rotterdam Scan Study
Vernooij, M. W., van der Lugt, A., Ikram, M. A., Wielopolski, P. A., Niessen, W. J., Hofman, A., Krestin, G. P., & Breteler, M. M. B. (2008) · Neurology · doi:10.1212/01.wnl.0000307750.41970.d9 · Cited by 793
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Self-citationRinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Self-citationWeller, R. O., Subash, M., Preston, S., Mazanti, I., & Carare, R. O. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00133.x · Cited by 697
Apolipoprotein E ϵ4 and cerebral hemorrhage associated with amyloid angiopathy
Greenberg, S. M., Rebeck, G. W., Vonsattel, J. P., Gómez‐Isla, T., & Hyman, B. T. (1995) · Annals of Neurology · doi:10.1002/ana.410380219 · Cited by 547
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1538 · Cited by 431
Clinical manifestations of cerebral amyloid angiopathy–related inflammation
Eng, J. A., Frosch, M. P., Choi, K., Rebeck, G. W., & Greenberg, S. M. (2004) · Annals of Neurology · doi:10.1002/ana.10810 · Cited by 417
Cited by
Sorted by citations
Items 201–300 of 506
Sun, T., Shi, Q., Zhang, Y., Power, C., Hoesch, C., Antonelli, S., Schroeder, M. K., Caldarone, B. J., Taudte, N., Schenk, M., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.037 · Cited by 41
Unraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab
Ameen, T. B., Kashif, S. N., Abbas, S. M. I., Babar, K., Ali, S. M. S., & Raheem, A. (2024) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-024-00845-5 · Cited by 43
Immunotherapy for Alzheimer's Disease: Current Scenario and Future Perspectives
Usman, M. B., Bhardwaj, S., Roychoudhury, S., Kumar, D., Alexiou, A. T., Kumar, P., Ambasta, R. K., Prasher, P., Shukla, S. D., Upadhye, V. J., et al. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.52 · Cited by 37
Potential Immunotargets for Alzheimer's Disease Treatment Strategies
Fernández, P. L., Britton, G. B., & Rao, K. S. J. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121222 · Cited by 38
Jeong, S. Y., Suh, C. H., Lim, J.-S., Shim, W. H., Heo, H., Choi, Y., Kim, H. S., Kim, S. J., & Lee, J.-H. (2025) · Neurology · doi:10.1212/wnl.0000000000213483 · Cited by 36
The neurobiology of Alzheimer disease defined by neuroimaging
Masdeu, J. C., Kreisl, W. C., & Berman, K. F. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283557b36 · Cited by 39
Kloske, C. M., Dugan, A. J., Weekman, E. M., Winder, Z., Patel, E., Nelson, P. T., Fardo, D. W., & Wilcock, D. M. (2021) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlab085 · Cited by 37
Advances in designs for Alzheimer's disease clinical trials.
Cummings, J. L., Gould, H. P., & Zhong, K. (2012) · Europe PMC (PubMed Central) · Cited by 37
Amyloid beta peptide immunotherapy in Alzheimer disease
Delrieu, J., Ousset, P., Voisin, T., & Vellas, B. J. (2014) · Revue Neurologique · doi:10.1016/j.neurol.2014.10.003 · Cited by 35
Pankiewicz, J. E., Baquero-Buitrago, J., Sanchez, S., Lopez-Contreras, J., Kim, J., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0156-1 · Cited by 34
“and cerebral microhemorrhages (ARIA-H) that in about 20% of cases are associated with clinical symptoms and signs [13, 14].”
BackgroundThe Role of Neuroinflammation in Neurodegenerative Disorders
Suescun, J., Chandra, S., & Schiess, M. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813832-8.00013-3 · Cited by 34
Advances in cerebral amyloid angiopathy imaging
Chen, S., Tsai, H.-H. C., Tsai, L., Tang, S., Lee, B., Liu, H., Yen, R., & Jeng, J. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419844113 · Cited by 35
Cerebral Superficial Siderosis
Weidauer, S., Neuhaus, E., & Hattingen, E. (2022) · Clinical Neuroradiology · doi:10.1007/s00062-022-01231-5 · Cited by 34
Roher, A. E., Cribbs, D. H., Kim, R. C., Maarouf, C. L., Whiteside, C. M., Kokjohn, T. A., Daugs, I. D., Head, E., Liebsack, C., Serrano, G. E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059735 · Cited by 34
Self-citationWerring, D. J., & Sperling, R. A. (2013) · Annals of Neurology · doi:10.1002/ana.23891 · Cited by 34
Self-citationSzalárdy, L., Fakan, B., Maszlag-Török, R., Ferencz, E., Reisz, Z., Radics, B., Csizmadia, S., Szpisjak, L., Annus, Á., Zádori, D., et al. (2023) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12946 · Cited by 33
Wang, T., Xie, X.-X., Ji, M., Wang, S., Zha, J., Zhou, W.-W., Yu, X., Chen, W., Ma, S., Xi, Z.-Y., et al. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.02.015 · Cited by 34
Hernandez, G. D., Solinsky, C. M., Mack, W. J., Kono, N., Rodgers, K. E., Wu, C., Mollo, A. R., Lopez, C. M., Pawluczyk, S., Bauer, G., et al. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12107 · Cited by 33
Largent, E. A., Bhardwaj, T., Abera, M., Stites, S. D., Harkins, K. A., Lerner, A. J., Bradbury, A. R., & Karlawish, J. H. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210675 · Cited by 34
Atwood, C., & Perry, G. L. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230040 · Cited by 33
RETRACTED ARTICLE: Gantenerumab for the treatment of Alzheimer's disease
Delrieu, J., Ousset, P., & Vellas, B. J. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.688022 · Cited by 32
RetractedCerebral Microbleeds as a Biomarker in Alzheimer’S Disease? A Review in The Field
Shams, S., & Wahlund, L.-O. (2016) · Biomarkers in Medicine · doi:10.2217/bmm.15.101 · Cited by 32
Brody, M., Liu, E., Di, J., Lu, M., Margolin, R. A., Werth, J. L., Booth, K., Shadman, A., Brashear, H. R., & Novak, G. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160369 · Cited by 32
Self-citationJackson, H. M., Onos, K. D., Pepper, K. W., Graham, L. C., Akeson, E. C., Byers, C., Reinholdt, L. G., Frankel, W. N., & Howell, G. R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125897 · Cited by 34
The Impact of Anti-Amyloid Immunotherapies on Stroke Care
Bilodeau, P., Dickson, J. R., & Kozberg, M. G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051245 · Cited by 32
Desai, A. A., Smith, M. D., Zhang, Y., Makowski, E. K., Gerson, J. E., Ionescu, E., Starr, C. G., Zupancic, J. M., Moore, S. J., Sutter, A. B., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100508 · Cited by 31
Ryan, N. S., Lashley, T., Révész, T., Dantu, K., Fox, N. C., & Morris, H. R. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142325 · Cited by 32
Self-citationGungor, I., Sarro, L., Graff-Radford, J., Zuk, S. M., Tosakulwong, N., Przybelski, S. A., Lesnick, T., Boeve, B. F., Ferman, T. J., Smith, G. E., et al. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.07.008 · Cited by 31
Specific Amyloid β Clearance by a Catalytic Antibody Construct
Planque, S. A., Nishiyama, Y., Sonoda, S., Lin, Y., Taguchi, H., Hara, M., Kolodziej, S. J., Mitsuda, Y., González‐Calle, V., Sait, H. B. R., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.641738 · Cited by 31
Kelly, L., Brown, C., Michalik, D., Hawkes, C. A., Aldea, R., Agarwal, N., Salib, R. J., Alzetani, A., Ethell, D. W., Counts, S., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13512 · Cited by 31
Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics
Ritter, A. R., & Cummings, J. L. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00186 · Cited by 29
Imaging as a biomarker in drug discovery for Alzheimer’s disease: is MRI a suitable technology?
Pich, E. M., Jeromin, A., Frisoni, G. B., Hill, D., Lockhart, A., Schmidt, M. E., Turner, M. R., Mondello, S., & Potter, W. Z. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt276 · Cited by 30
Intracellular FRET-based Screen for Redesigning the Specificity of Secreted Proteases
Guerrero, J. L., O’Malley, M., & Daugherty, P. S. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b01051 · Cited by 29
Li, D., Iddi, S., Thompson, W. K., Rafii, M. S., Aisen, P. S. S., Donohue, M., & Initiative, A. D. N. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.07.008 · Cited by 29
Potential Therapeutic Approaches for Cerebral Amyloid Angiopathy and Alzheimer’s Disease
Tanaka, M., Saitô, S., Inoue, T., Satoh‐Asahara, N., & Ihara, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061992 · Cited by 31
Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease
Joseph‐Mathurin, N., Wang, G., Kantarci, K., Jack, C. R., McDade, E., Hassenstab, J. J., Blazey, T., Gordon, B. A., Su, Y., Chen, G., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011542 · Cited by 28
Self-citationTachida, Y., Miura, S., Imamaki, R., Ogasawara, N., Takuwa, H., Sahara, N., Shindo, A., Matsuba, Y., Saito, T., Taniguchi, N., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101880 · Cited by 28
Salemme, S., Ancidoni, A., Locuratolo, N., Piscopo, P., Lacorte, E., Canevelli, M., & Vanacore, N. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2284305 · Cited by 28
Grill, J. D., Raman, R., Ernstrom, K. B., Aisen, P. S. S., Dowsett, S. A., Chen, Y.-F., Liu‐Seifert, H., Hake, A. M., Miller, D. S., Doody, R. S., et al. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0122-5 · Cited by 29
Bogner, S., Bernreuther, C., Matschke, J., Barrera-Ocampo, A. A., Falla, D. S., Leypoldt, F., Magnus, T. U., Haag, F., Bergmann, M., Brück, W., et al. (2013) · Neurodegenerative Diseases · doi:10.1159/000352020 · Cited by 28
Alzheimer's disease drug development: translational neuroscience strategies
Cummings, J. L., Banks, S. J., Gary, R. K., Kinney, J. W., Lombardo, J. M., Walsh, R. R., & Zhong, K. (2013) · CNS Spectrums · doi:10.1017/s1092852913000023 · Cited by 27
Smedinga, M., Darweesh, S. K. L., Bloem, B. R., Post, B., & Richard, E. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10162-5 · Cited by 28
Beyond the amyloid cascade: An update of Alzheimer's disease pathophysiology
Gouilly, D., Rafiq, M., Nogueira, L., Salabert, A., Payoux, P., Péran, P., & Pariente, J. (2023) · Revue Neurologique · doi:10.1016/j.neurol.2022.12.006 · Cited by 31
Neumann, U., Machauer, R., & Shimshek, D. R. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14582 · Cited by 27
Froestl, W., Pfeifer, A., & Muhs, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121729 · Cited by 27
Jeong, S. Y., Suh, C. H., Kim, S. J., Lemere, C. A., Lim, J.-S., & Lee, J.-H. (2024) · Korean Journal of Radiology · doi:10.3348/kjr.2024.0105 · Cited by 26
“It is hypothesized that when immunotherapy is initiated, monoclonal antibodies bind to accumulated A β in the cerebral parenchyma and cerebral vessels [18,19].”
BackgroundDavis, P. R., Giannini, G., Rudolph, K., Calloway, N. T., Royer, C. M., Beckett, T. L., Murphy, M. P., Bresch, F., Pagani, D., Platt, T. L., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.09.007 · Cited by 26
A short perspective on the long road to effective treatments for Alzheimer's disease
Reynolds, D. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14581 · Cited by 28
Willumsen, N., Poole, T., Nicholas, J. M., Fox, N. C., Ryan, N. S., & Lashley, T. (2021) · Brain Pathology · doi:10.1111/bpa.13009 · Cited by 25
Self-citationBobbins, A., Davies, M., Lynn, E., Roy, D., Yeomans, A., & Shakir, S. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70021 · Cited by 24
Efficient amyloid-β degradation in Alzheimer’s disease using SPYTACs
Teng, F., Liu, J., Cui, T., Tan, X., Liu, K., Hou, Z., (54356), L. Z., Xie, Y., Li, R., Li, D., et al. (2026) · Cell · doi:10.1016/j.cell.2026.01.034 · Cited by 25
Amyloid imaging in clinical trials
Ossenkoppele, R., Prins, N. D., & van Berckel, B. N. M. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt195 · Cited by 24
Therapeutic anti‐amyloid β antibodies cause neuronal disturbances
Adhikari, U. K., Khan, R. H., Mikhael, M., Balez, R., David, M. A., Mahns, D. A., Hardy, J., & Tayebi, M. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12833 · Cited by 24
Banerjee, G., Alvares, D., Bowen, J., Adams, M. E., & Werring, D. J. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317347 · Cited by 24
Takatori, S., Kondo, M., & Tomita, T. (2025) · Inflammation and Regeneration · doi:10.1186/s41232-025-00383-4 · Cited by 28
Targeting soluble amyloid-beta oligomers with a novel nanobody
Haynes, J. R., Whitmore, C. A., Behof, W. J., Landman, C. A., Ong, H. H., Feld, A. P., Suero, I. C., Greer, C. B., Gore, J. C., Wijesinghe, P., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-66970-6 · Cited by 23
Raman, M. R., Kantarci, K., Murray, M. E., Jack, C. R., & Vemuri, P. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.12.006 · Cited by 23
Passive immunotherapy for Alzheimer's disease: What have we learned, and where are we headed?
Aisen, P. S. S., & Vellas, B. J. (2013) · The journal of nutrition health & aging · doi:10.1007/s12603-013-0001-3 · Cited by 24
Blockx, I., Einstein, S., Guns, P., Audekerke, J. V., Guglielmetti, C., Zago, W. M., Roose, D., Verhoye, M., der Linden, A. V., & Bard, F. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160023 · Cited by 23
Future Directions in Imaging Neurodegeneration
Masdeu, J. C. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0718-1 · Cited by 22
Majid, O., Cao, Y., Willis, B. A., Hayato, S., Takenaka, O., Lalovic, B. B., Reddy, S. H. S., Penner, N., Reyderman, L., Yasuda, S., et al. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13224 · Cited by 21
Use of Artificial Intelligence in Imaging Dementia
Aljuhani, M., Ashraf, A., & Edison, P. (2024) · Cells · doi:10.3390/cells13231965 · Cited by 21
Schreiner, S. J., Liu, X., Gietl, A. F., Wyss, M., Steininger, S. C., Gruber, E., Treyer, V., Meier, I. B., Kälin, A. M., Leh, S. E., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00240 · Cited by 21
Salloway, S., Sperling, R. A., Fox, N. C., Sabbagh, M. N., Honig, L. S., Porsteinsson, A. P., Rofael, H. Z., Ketter, N., Wang, D., Liu, E., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171157 · Cited by 21
Self-citationDual orexin receptor antagonists as promising therapeutics for Alzheimer’s disease
Ragsdale, S. M., Radovich, J. M., Coiduras, I. I., McCall, W. V., Grant, S. C., Lee, C. S., & Wilber, A. A. (2025) · npj Biological Timing and Sleep · doi:10.1038/s44323-025-00025-5 · Cited by 20
Immunotherapy for Alzheimer’s Disease
Farlow, M. R., & Brosch, J. R. (2013) · Neurologic Clinics · doi:10.1016/j.ncl.2013.03.012 · Cited by 20
Scherlek, A. A., Kozberg, M. G., Nicoll, J. A. R., Perosa, V., Freeze, W. M., van der Weerd, L., Bacskai, B. J., Greenberg, S. M., Frosch, M. P., Boche, D., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac021 · Cited by 20
Biomarker-Driven Therapeutic Management of Alzheimer’s Disease: Establishing the Foundations
Cummings, J. L., & Zhong, K. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.205 · Cited by 21
Head, E., Powell, D. K., & Schmitt, F. A. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00191 · Cited by 20
Current insights into apolipoprotein E and the immune response in Alzheimer's disease
Lin, P. B., & Holtzman, D. M. (2024) · Immunological Reviews · doi:10.1111/imr.13414 · Cited by 19
Marković, M., Milošević, J. R., Wang, W., & Cao, Y. (2023) · Molecular Pharmacology · doi:10.1124/molpharm.123.000726 · Cited by 20
Fernández-Fúnez, P., Zhang, Y., Sanchez-Garcia, J., de Mena, L., Khare, S., Golde, T. E., Levites, Y., & Rincón-Limas, D. E. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv321 · Cited by 19
Alzheimer Disease and Cellular Mechanisms of Memory Storage
Arshavsky, Y. I. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000043 · Cited by 19
A Rational Structured Epitope Defines a Distinct Subclass of Toxic Amyloid-beta Oligomers
Silverman, J. M., Gibbs, E., Peng, X., Martens, K. M., Balducci, C., Wang, J., Yousefi, M., Cowan, C. M., Lamour, G., Louadi, S., et al. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00469 · Cited by 21
AMBAR, an Encouraging Alzheimer's Trial That Raises Questions
Loeffler, D. A. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00459 · Cited by 20
McNally, J. S., Sakata, A., Alexander, M. D., Dewitt, L. D., Sonnen, J. A., Menacho, S. T., Stoddard, G. J., Kim, S.-E., & de Havenon, A. H. (2021) · American Journal of Neuroradiology · doi:10.3174/ajnr.a7047 · Cited by 18
Janssens, J., Hermans, B., Vandermeeren, M., Barale-Thomas, E., Borgers, M., Willems, R., Meulders, G., Wintmolders, C., den Bulck, D. V., Bottelbergs, A., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105365 · Cited by 18
Role of Pharmacogenomics in Individualizing Treatment for Alzheimer’s Disease
Argueta, N., Notari, E., & Szigeti, K. (2022) · CNS Drugs · doi:10.1007/s40263-022-00915-3 · Cited by 18
Martín‐Peña, A., Rincón-Limas, D. E., & Fernández-Fúnez, P. (2017) · Scientific Reports · doi:10.1038/s41598-017-11594-2 · Cited by 18
Honey and Alzheimer’s Disease—Current Understanding and Future Prospects
Shaikh, A., Ahmad, F., Teoh, S. L., Kumar, J., & Yahaya, M. F. (2023) · Antioxidants · doi:10.3390/antiox12020427 · Cited by 19
Development of disease‐modifying therapies against Alzheimer's disease
Iwatsubo, T. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13681 · Cited by 20
Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease
Ameen, T. B., Ali, U., Salma, O., Samee, M. A., Abbas, S. M. I., Kashif, S. N., Arifi, M. A., Ali, M., Khowaja, M., Ali, S. M. S., et al. (2025) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-025-00968-3 · Cited by 20
Ghura, S., Tai, L. M., Zhao, M., Collins, N., Che, C., Warpeha, K. M., & LaDu, M. J. (2016) · Scientific Reports · doi:10.1038/srep29364 · Cited by 17
Roda, A. R., Montoliu‐Gaya, L., Serra-Mir, G., & Villegas, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186630 · Cited by 17
Goeldlin, M. B., Stewart, C. R., Radojewski, P., Wiest, R., Seiffge, D. J., & Werring, D. J. (2022) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2022.2104157 · Cited by 17
Boustani, M. A., Doty, E. G., Garrison, L. P., Smolen, L. J., Belger, M. A., Klein, T. M., Murphy, D. R., Burge, R. T., Wall, J. K., & Johnston, J. A. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.09.008 · Cited by 17
Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease
Sha, S., Ren, L., Xing, X., Guo, W., Wang, Y., Li, Y., Cao, Y., & Qu, L. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00846 · Cited by 16
Combination Therapy for the Treatment of Alzheimer’s Disease: Recent Progress and Future Prospects
Shirbhate, E., Patel, V. K., Tiwari, P., Kore, R., Veerasamy, R., Mishra, A., & Rajak, H. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220907114443 · Cited by 18
Recent Trends in Active and Passive Immunotherapies of Alzheimer’s Disease
Alshamrani, M. (2023) · Antibodies · doi:10.3390/antib12020041 · Cited by 17
Updates on pharmacological treatment for Alzheimer’s disease
Tipton, P. W. (2023) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.96286 · Cited by 16
Cerebral amyloid angiopathy and the immune system
Munsterman, D., Falcione, S. R., Long, R., Boghozian, R., Joy, T., Camicioli, R. M., Smith, E. E., & Jickling, G. C. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13826 · Cited by 16
Engineered Antibodies to Improve Efficacy against Neurodegenerative Disorders
Niazi, S. K., Mariam, Z., & Magoola, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126683 · Cited by 16
Barbosa, B. J. A. P., Resende, E. D. P. F., Castilhos, R. M., Borelli, W. V., Frota, N. A. F., Balthazar, M. L. F., Filho, A. C. S. A., Smid, J., Barbosa, M. T., Coutinho, A. M., et al. (2024) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2024-c002 · Cited by 17
Kudrna, J. J., & Ugen, K. E. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1065364 · Cited by 16
Wang, Y., Yu, Q., Chen, B., Zhou, J., Li, Z., Liao, W., Liu, J., & Yang, A. (2025) · BMC Neurology · doi:10.1186/s12883-025-04302-5 · Cited by 15
Management of intracerebral hemorrhage – use of statins
Kiser, T. H., Matre, E. T. V., & Sherman, D. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s75399 · Cited by 15
Neuroimaging of Diseases Causing Dementia
Masdeu, J. C. (2019) · Neurologic Clinics · doi:10.1016/j.ncl.2019.08.003 · Cited by 16
Primary angiitis of the central nervous system – A challenging diagnosis
Paul, S. A., Roy, D., Mondal, G. P., Bhattacharyya, R., Ghosh, K. C., Das, S., Krishna, H., Patra, C., Kiran, J., & Benito‐León, J. (2022) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2022.577844 · Cited by 15
Aldea, R., Grimm, H. P., Gieschke, R., Hofmann, C., Lott, D., Bullain, S., Delmar, P., Klein, G., Lyons, M., Piazza, F., et al. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12306 · Cited by 15
Emerging amyloid and tau targeting treatments for Alzheimer’s disease
Khan, A., Corbett, A., & Ballard, C. G. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1326819 · Cited by 16
Metadata
- Authors
- Sperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Lieberburg, I., Arrighi, H. M., Morris, K. A., Lu, Y., Liu, E., Gregg, K. M., Brashear, H. R., Kinney, G. G., Black, R., & Grundman, M.
- Affiliations
- Brigham and Women's Hospital (US)
- Butler Hospital (US)
- Imperial College London (GB)
- McGill University (CA)
- California Pacific Medical Center (US)
- UCL Queen Square Institute of Neurology (GB)
- Columbia University (US)
- University of Rochester Medicine (US)
- University of California, San Francisco (US)
- Janssen Alzheimer Immunotherapy Research & Development (United States) (US)
- Corresponding author
- Sperling, Reisa
- ORCID
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 11
- Issue
- 3
- Pages
- 241-249
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC4063417
- OpenAlex
- W2122843800
- Cited by
- 512
- References
- 27
- Citations by year
- 2026: 25 · 2025: 41 · 2024: 51 · 2023: 35 · 2022: 47 · 2021: 32 · 2020: 31 · 2019: 25 · 2018: 22 · 2017: 34 · 2016: 29 · 2015: 47 · 2014: 36 · 2013: 39 · 2012: 17
- FWCI
- 29.81
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0508-10123)
- Elan
- National Institute on Aging (K24AG035007, P50AG005134, P30AG062421)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Keywords
- amyloid-related imaging abnormalities, bapineuzumab, Alzheimer's disease, amyloid-beta, ARIA-E, ARIA-H, vasogenic edema, microhemorrhages, APOE ε4, dose-dependent risk, risk factors, FLAIR MRI, adverse events
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Retrospective Studies, Risk Factors, Amyloid beta-Peptides, Neuroimaging, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
